Cargando…

Novel targeted therapies for Parkinson’s disease

Parkinson’s disease (PD) is the second more common neurodegenerative disease with increasing incidence worldwide associated to the population ageing. Despite increasing awareness and significant research advancements, treatment options comprise dopamine repleting, symptomatic therapies that have sig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ntetsika, Theodora, Papathoma, Paraskevi-Evita, Markaki, Ioanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905684/ https://www.ncbi.nlm.nih.gov/pubmed/33632120 http://dx.doi.org/10.1186/s10020-021-00279-2

Ejemplares similares

A replication study, systematic review and meta-analysis of automated image-based diagnosis in parkinsonism
por: Papathoma, Paraskevi-Evita, et al.
Publicado: (2022)

Novel Treatment Opportunities Against Cognitive Impairment in Parkinson’s Disease with an Emphasis on Diabetes-Related Pathways
por: Green, Holly, et al.
Publicado: (2019)

Pupil light reflex dynamics in Parkinson’s disease
por: Tsitsi, Panagiota, et al.
Publicado: (2023)

Reading Alterations in Parkinson's Disease Indicate Worse Cognitive Status
por: Tsitsi, Panagiota, et al.
Publicado: (2023)

Fixation Duration and Pupil Size as Diagnostic Tools in Parkinson’s Disease
por: Tsitsi, Panagiota, et al.
Publicado: (2021)

Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease
por: Paslawski, Wojciech, et al.
Publicado: (2023)

Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic
por: Sardi, S. Pablo, et al.
Publicado: (2018)

Glycosphingolipid Changes in Plasma in Parkinson's Disease Independent of Glucosylceramide Levels
por: te Vruchte, Danielle, et al.
Publicado: (2022)

Is the Enzyme ACMSD a Novel Therapeutic Target in Parkinson’s Disease?
por: Thirtamara-Rajamani, Keerthi, et al.
Publicado: (2017)

Progress in circRNA-Targeted Therapy in Experimental Parkinson’s Disease
por: Titze-de-Almeida, Simoneide Souza, et al.
Publicado: (2023)

Parkinson’s disease and translational research
por: Dinter, Elisabeth, et al.
Publicado: (2020)

Targeting Histone Deacetylases: A Novel Approach in Parkinson's Disease
por: Sharma, Sorabh, et al.
Publicado: (2015)

LRRK2 and Parkinson's disease: from genetics to targeted therapy
por: Sosero, Yuri L., et al.
Publicado: (2023)

Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy
por: Lecht, Shimon, et al.
Publicado: (2007)

Therapy of Parkinson's Disease
por: Holzer, Jacob C.
Publicado: (1990)

Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson’s Disease
por: Zella, Maria Angela Samis, et al.
Publicado: (2019)

Gaps and roadmap of novel neuromodulation targets for treatment of gait in Parkinson’s disease
por: Cury, Rubens Gisbert, et al.
Publicado: (2022)

Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease
por: Nowell, Joseph, et al.
Publicado: (2022)

GBA1 Variants and Parkinson’s Disease: Paving the Way for Targeted Therapy
por: Huh, Young Eun, et al.
Publicado: (2023)

Current and novel infusion therapies for patients with Parkinson's disease
por: Antonini, Angelo, et al.
Publicado: (2023)

Editorial: Body fluid biomarkers in neurodegenerative studies: Novel insights into pathophysiology to support clinical practice and drug development
por: Bougea, Anastasia, et al.
Publicado: (2023)

Neurotrophic factors: from neurodevelopmental regulators to novel therapies for Parkinson's disease
por: Hegarty, Shane V., et al.
Publicado: (2014)

Targeting mitophagy in Parkinson's disease
por: Clark, Emily H., et al.
Publicado: (2020)

Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease
por: Zhang, Kai, et al.
Publicado: (2021)

Novel Pharmacotherapies in Parkinson’s Disease
por: Tizabi, Yousef, et al.
Publicado: (2021)

Biologic Therapies and Autoimmune Phenomena
por: Drosos, Alexandros A., et al.
Publicado: (2021)

Transcriptional Factor NF-κB as a Target for Therapy in Parkinson's Disease
por: Flood, Patrick M., et al.
Publicado: (2011)

Gene Therapy for Parkinson's Disease
por: Denyer, Rachel, et al.
Publicado: (2012)

Cell Therapy for Parkinson’s Disease
por: MORIZANE, Asuka, et al.
Publicado: (2016)

Endogenous versus exogenous cell replacement for Parkinson’s disease: where are we at and where are we going?
por: Mourtzi, Theodora, et al.
Publicado: (2022)

Drug therapy in patients with Parkinson’s disease
por: Müller, Thomas
Publicado: (2012)

Gene Therapy for Parkinson’s Disease, An Update
por: Axelsen, Tobias M., et al.
Publicado: (2018)

CDNF Protein Therapy in Parkinson’s Disease
por: Huttunen, Henri J., et al.
Publicado: (2019)

Infusion Therapies in the Treatment of Parkinson’s Disease
por: van Laar, Teus, et al.
Publicado: (2023)

Neurocognitive profile of adults with the Norrbottnian type of Gaucher disease
por: Tsitsi, Panagiota, et al.
Publicado: (2021)

Ceramide Metabolism and Parkinson’s Disease—Therapeutic Targets
por: Custodia, Antía, et al.
Publicado: (2021)

Mitochondria: A Therapeutic Target for Parkinson’s Disease?
por: Luo, Yu, et al.
Publicado: (2015)

Emerging preclinical pharmacological targets for Parkinson's disease
por: More, Sandeep Vasant, et al.
Publicado: (2016)

Secretome as neuropathology-targeted intervention of Parkinson’s disease
por: Ardianto, Christian, et al.
Publicado: (2022)

Targeting the cholinergic system in Parkinson’s disease
por: Liu, Changliang
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5dg1r5cbiuqjjimlvj4brldlsd